london surgical oncology limited
london surgical oncology limited Company Information
Company Number
08418086
Website
-Registered Address
4 beaumont, 4-6 st johns avenue, london, SW15 2AF
Industry
Other human health activities
Telephone
02088744905
Next Accounts Due
November 2024
Group Structure
View All
Shareholders
zainab syed 50%
aamir khan 50%
london surgical oncology limited Estimated Valuation
The estimated valuation range for london surgical oncology limited, derived from financial data as of February 2023 and the most recent industry multiples, is between £0 to £8.9m
london surgical oncology limited Estimated Valuation
The estimated valuation range for london surgical oncology limited, derived from financial data as of February 2023 and the most recent industry multiples, is between £0 to £8.9m
london surgical oncology limited Estimated Valuation
The estimated valuation range for london surgical oncology limited, derived from financial data as of February 2023 and the most recent industry multiples, is between £0 to £8.9m
Get a detailed valuation report, edit figures and unlock valuation multiples.
London Surgical Oncology Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
London Surgical Oncology Limited Overview
London Surgical Oncology Limited is a live company located in london, SW15 2AF with a Companies House number of 08418086. It operates in the other human health activities sector, SIC Code 86900. Founded in February 2013, it's largest shareholder is zainab syed with a 50% stake. London Surgical Oncology Limited is a established, micro sized company, Pomanda has estimated its turnover at £151.1k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
London Surgical Oncology Limited Health Check
Pomanda's financial health check has awarded London Surgical Oncology Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs
3 Strong
2 Regular
5 Weak
Size
annual sales of £151.1k, make it smaller than the average company (£658.3k)
- London Surgical Oncology Limited
£658.3k - Industry AVG
Growth
3 year (CAGR) sales growth of -12%, show it is growing at a slower rate (5.2%)
- London Surgical Oncology Limited
5.2% - Industry AVG
Production
with a gross margin of 37.2%, this company has a comparable cost of product (37.2%)
- London Surgical Oncology Limited
37.2% - Industry AVG
Profitability
an operating margin of -107.3% make it less profitable than the average company (6.9%)
- London Surgical Oncology Limited
6.9% - Industry AVG
Employees
with 2 employees, this is below the industry average (17)
2 - London Surgical Oncology Limited
17 - Industry AVG
Pay Structure
on an average salary of £24.3k, the company has an equivalent pay structure (£24.3k)
- London Surgical Oncology Limited
£24.3k - Industry AVG
Efficiency
resulting in sales per employee of £75.5k, this is more efficient (£45.5k)
- London Surgical Oncology Limited
£45.5k - Industry AVG
Debtor Days
it gets paid by customers after 39 days, this is later than average (23 days)
- London Surgical Oncology Limited
23 days - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- London Surgical Oncology Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- London Surgical Oncology Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 1475 weeks, this is more cash available to meet short term requirements (126 weeks)
1475 weeks - London Surgical Oncology Limited
126 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 2.8%, this is a lower level of debt than the average (24.8%)
2.8% - London Surgical Oncology Limited
24.8% - Industry AVG
london surgical oncology limited Credit Report and Business Information
London Surgical Oncology Limited Competitor Analysis
Perform a competitor analysis for london surgical oncology limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
london surgical oncology limited Ownership
LONDON SURGICAL ONCOLOGY LIMITED group structure
London Surgical Oncology Limited has no subsidiary companies.
Ultimate parent company
LONDON SURGICAL ONCOLOGY LIMITED
08418086
london surgical oncology limited directors
London Surgical Oncology Limited currently has 2 directors. The longest serving directors include Mrs Syed Zainab (Feb 2013) and Mr Aamir Khan (Feb 2013).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mrs Syed Zainab | United Kingdom | 48 years | Feb 2013 | - | Director |
| Mr Aamir Khan | United Kingdom | 54 years | Feb 2013 | - | Director |
LONDON SURGICAL ONCOLOGY LIMITED financials
London Surgical Oncology Limited's latest turnover from February 2023 is estimated at £151.1 thousand and the company has net assets of £3.6 million. According to their latest financial statements, London Surgical Oncology Limited has 2 employees and maintains cash reserves of £2.9 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | Feb 2016 | Feb 2015 | Feb 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||||
| Other Income Or Grants | ||||||||||
| Cost Of Sales | ||||||||||
| Gross Profit | ||||||||||
| Admin Expenses | ||||||||||
| Operating Profit | ||||||||||
| Interest Payable | ||||||||||
| Interest Receivable | ||||||||||
| Pre-Tax Profit | ||||||||||
| Tax | ||||||||||
| Profit After Tax | ||||||||||
| Dividends Paid | ||||||||||
| Retained Profit | ||||||||||
| Employee Costs | ||||||||||
| Number Of Employees | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | Feb 2016 | Feb 2015 | Feb 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 324 | 432 | 576 | 697 | 858 | 1,072 | 56 | 56 | 56 | 75 |
| Intangible Assets | 350,000 | 350,000 | 350,000 | 350,000 | 350,000 | 350,000 | 350,000 | 350,000 | 350,000 | 350,000 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 350,324 | 350,432 | 350,576 | 350,697 | 350,858 | 351,072 | 350,056 | 350,056 | 350,056 | 350,075 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 16,350 | 18,500 | 14,527 | 28,122 | 239,416 | 316,633 | 330,145 | 314,430 | 299,560 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 79,352 |
| Misc Debtors | 412,565 | 458,187 | 467,354 | 458,187 | 458,187 | 335,427 | 235,427 | 0 | 0 | 0 |
| Cash | 2,914,876 | 2,851,929 | 2,874,090 | 3,076,894 | 2,416,816 | 1,597,509 | 1,228,180 | 747,126 | 339,419 | 180,728 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 3,343,791 | 3,328,616 | 3,355,971 | 3,563,203 | 3,114,419 | 2,249,569 | 1,793,752 | 1,061,556 | 638,979 | 260,080 |
| total assets | 3,694,115 | 3,679,048 | 3,706,547 | 3,913,900 | 3,465,277 | 2,600,641 | 2,143,808 | 1,411,612 | 989,035 | 610,155 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 479,339 | 464,469 | 422,870 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 102,761 | 40,908 | 54,105 | 186,571 | 464,379 | 431,087 | 485,753 | 0 | 0 | 0 |
| total current liabilities | 102,761 | 40,908 | 54,105 | 186,571 | 464,379 | 431,087 | 485,753 | 479,339 | 464,469 | 422,870 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 102,761 | 40,908 | 54,105 | 186,571 | 464,379 | 431,087 | 485,753 | 479,339 | 464,469 | 422,870 |
| net assets | 3,591,354 | 3,638,140 | 3,652,442 | 3,727,329 | 3,000,898 | 2,169,554 | 1,658,055 | 932,273 | 524,566 | 187,285 |
| total shareholders funds | 3,591,354 | 3,638,140 | 3,652,442 | 3,727,329 | 3,000,898 | 2,169,554 | 1,658,055 | 932,273 | 524,566 | 187,285 |
| Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | Feb 2016 | Feb 2015 | Feb 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Operating Profit | ||||||||||
| Depreciation | 108 | 144 | 121 | 161 | 214 | 0 | 0 | 0 | 19 | 25 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | ||||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -47,772 | -5,194 | -4,428 | -211,294 | 45,543 | 86,488 | 251,142 | 14,870 | 220,208 | 79,352 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | -479,339 | 14,870 | 41,599 | 422,870 |
| Accruals and Deferred Income | 61,853 | -13,197 | -132,466 | -277,808 | 33,292 | -54,666 | 485,753 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||||||||
| Investing Activities | ||||||||||
| capital expenditure | ||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||
| Financing Activities | ||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||
| interest | ||||||||||
| cash flow from financing | ||||||||||
| cash and cash equivalents | ||||||||||
| cash | 62,947 | -22,161 | -202,804 | 660,078 | 819,307 | 369,329 | 481,054 | 407,707 | 158,691 | 180,728 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 62,947 | -22,161 | -202,804 | 660,078 | 819,307 | 369,329 | 481,054 | 407,707 | 158,691 | 180,728 |
P&L
February 2023turnover
151.1k
-13%
operating profit
-162.1k
0%
gross margin
37.2%
+4.66%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
February 2023net assets
3.6m
-0.01%
total assets
3.7m
0%
cash
2.9m
+0.02%
net assets
Total assets minus all liabilities
Similar Companies
london surgical oncology limited company details
company number
08418086
Type
Private limited with Share Capital
industry
86900 - Other human health activities
incorporation date
February 2013
age
11
accounts
Total Exemption Full
ultimate parent company
previous names
N/A
incorporated
UK
address
4 beaumont, 4-6 st johns avenue, london, SW15 2AF
last accounts submitted
February 2023
london surgical oncology limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to london surgical oncology limited.
london surgical oncology limited Companies House Filings - See Documents
| date | description | view/download |
|---|
